Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,433 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A single-arm confirmatory trial of pazopanib in patients with paclitaxel-pretreated primary cutaneous angiosarcoma: Japan Clinical Oncology Group study (JCOG1605, JCOG-PCAS protocol).
Oashi K, Shibata T, Namikawa K, Takahashi A, Yokota K, Nakano E, Teramoto Y, Tsutsumida A, Maeda T, Yamazaki N; Dermatologic Oncology Group of the Japan Clinical Oncology Group. Oashi K, et al. Among authors: yokota k. BMC Cancer. 2020 Jul 13;20(1):652. doi: 10.1186/s12885-020-07136-1. BMC Cancer. 2020. PMID: 32660439 Free PMC article.
Frequency of level II and III axillary nodes metastases in patients with positive sentinel lymph nodes in melanoma: a multi-institutional study in Japan.
Tsutsumida A, Takahashi A, Namikawa K, Yamazaki N, Uhara H, Teramoto Y, Takenouchi T, Fukushima S, Yokota K, Uehara J, Matsushita S, Shibayama Y, Hatta N, Masui Y, Uchi H, Fujisawa Y, Ogata D. Tsutsumida A, et al. Among authors: yokota k. Int J Clin Oncol. 2016 Aug;21(4):796-800. doi: 10.1007/s10147-015-0944-y. Epub 2016 Jan 13. Int J Clin Oncol. 2016. PMID: 26759315
Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041).
Yamazaki N, Takenouchi T, Fujimoto M, Ihn H, Uchi H, Inozume T, Kiyohara Y, Uhara H, Nakagawa K, Furukawa H, Wada H, Noguchi K, Shimamoto T, Yokota K. Yamazaki N, et al. Among authors: yokota k. Cancer Chemother Pharmacol. 2017 Apr;79(4):651-660. doi: 10.1007/s00280-016-3237-x. Epub 2017 Mar 11. Cancer Chemother Pharmacol. 2017. PMID: 28283736 Free PMC article. Clinical Trial.
Japanese real-world study of sequential nivolumab and ipilimumab treament in melanoma.
Tsutsumida A, Fukushima S, Yokota K, Yoshikawa S, Yamasaki O, Tanemura A, Okuyama R, Uhara H, Muto Y, Miyashita A, Akiyama M, Kaji T, Koga H, Kato J, Katayama T, Itakura E, Yamazaki N, Kiyohara Y. Tsutsumida A, et al. Among authors: yokota k. J Dermatol. 2019 Nov;46(11):947-955. doi: 10.1111/1346-8138.15073. Epub 2019 Sep 17. J Dermatol. 2019. PMID: 31531895
Concordance in judgment of clinical borders of basal cell carcinomas in Japanese patients: A preliminary study of JCOG2005 (J-BASE-MARGIN).
Kamimura A, Nakamura Y, Takenouchi T, Matsushita S, Omodaka T, Yamamura K, Uchi H, Yoshikawa S, Yanagisawa H, Ito T, Kiyohara Y, Nakamura Y, Aoki M, Ishizuki S, Oashi K, Miyagawa T, Maeda T, Ogata D, Hatta N, Ohe S, Isei T, Takahashi A, Umeda Y, Yamaguchi B, Ishikawa M, Horimoto K, Fujsawa Y, Uehara J, Shibayama Y, Kiniwa Y, Kawahara Y, Matsuya T, Uhara H, Kato J, Nakamura Y, Murakami T, Namikawa K, Yoshino K, Funakoshi T, Takatsuka S, Matsui Y, Sasaki J, Koga H, Yokota K, Komori T, Fukushima S, Yamazaki N. Kamimura A, et al. Among authors: yokota k. J Dermatol. 2022 Sep;49(9):837-844. doi: 10.1111/1346-8138.16422. Epub 2022 May 5. J Dermatol. 2022. PMID: 35510662
Anti-PD-1 antibody therapy for epithelial skin malignancies: An investigator-initiated, open-label, single-arm, multicenter, phase II clinical trial (NMSC-PD1 Study).
Ishii M, Hirai I, Tanese K, Fusumae T, Nakamura Y, Fukuda K, Uchi H, Kabashima K, Otsuka A, Yokota K, Yamazaki N, Namikawa K, Fujimura T, Takenouchi T, Yamamoto Y, Nishiguchi M, Sato Y, Amagai M, Funakoshi T. Ishii M, et al. Among authors: yokota k. Medicine (Baltimore). 2020 Oct 30;99(44):e22913. doi: 10.1097/MD.0000000000022913. Medicine (Baltimore). 2020. PMID: 33126349 Free PMC article.
Clinical and histopathological characteristics and survival analysis of 4594 Japanese patients with melanoma.
Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, Noma N, Nakamura Y, Asai J, Kato J, Fujiwara S, Fukushima S, Uehara J, Hoashi T, Kaji T, Fujimura T, Namikawa K, Yoshioka M, Murao N, Ogata D, Matsuyama K, Hatta N, Shibayama Y, Fujiyama T, Ishikawa M, Yamada D, Kishi A, Nakamura Y, Shimiauchi T, Fujii K, Fujimoto M, Ihn H, Katoh N. Fujisawa Y, et al. Among authors: yokota k. Cancer Med. 2019 May;8(5):2146-2156. doi: 10.1002/cam4.2110. Epub 2019 Apr 1. Cancer Med. 2019. PMID: 30932370 Free PMC article.
Classification of 3097 patients from the Japanese melanoma study database using the American joint committee on cancer eighth edition cancer staging system.
Fujisawa Y, Yoshikawa S, Minagawa A, Takenouchi T, Yokota K, Uchi H, Noma N, Nakamura Y, Asai J, Kato J, Fujiwara S, Fukushima S, Uehara J, Hoashi T, Kaji T, Fujimura T, Namikawa K, Yoshioka M, Murata N, Ogata D, Matsuyama K, Hatta N, Shibayama Y, Fujiyama T, Ishikawa M, Yamada D, Kishi A, Nakamura Y, Shimiauchi T, Fujii K, Fujimoto M, Ihn H, Katoh N. Fujisawa Y, et al. Among authors: yokota k. J Dermatol Sci. 2019 May;94(2):284-289. doi: 10.1016/j.jdermsci.2019.04.003. Epub 2019 Apr 17. J Dermatol Sci. 2019. PMID: 31023613
Adjuvant therapy with nivolumab versus ipilimumab after complete resection of stage III/IV melanoma: Japanese subgroup analysis from the phase 3 CheckMate 238 study.
Yokota K, Uchi H, Uhara H, Yoshikawa S, Takenouchi T, Inozume T, Ozawa K, Ihn H, Fujisawa Y, Qureshi A, de Pril V, Otsuka Y, Weber J, Yamazaki N. Yokota K, et al. J Dermatol. 2019 Dec;46(12):1197-1201. doi: 10.1111/1346-8138.15103. Epub 2019 Oct 22. J Dermatol. 2019. PMID: 31638282 Free PMC article. Clinical Trial.
1,433 results